WallStreetZenWallStreetZen

NASDAQ: EXEL
Exelixis Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

EXEL past earnings growth

How has EXEL's earnings growth performed historically?
Company
14.04%
Industry
54.16%
Market
72.61%
EXEL's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
EXEL's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
EXEL's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

EXEL past revenue growth

How has EXEL's revenue growth performed historically?
Company
13.6%
Industry
144.63%
Market
17.55%
EXEL's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
EXEL's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
EXEL's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

EXEL earnings and revenue history

Current Revenue
$1.8B
Current Earnings
$207.8M
Current Profit Margin
11.4%

EXEL Return on Equity

Current Company
8.6%
Current Industry
-63.5%
Current Market
188%
EXEL's Return on Equity (8.6%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when EXEL announces earnings.

EXEL Return on Assets

Current Company
6.8%
Current Industry
2.9%
EXEL is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

EXEL Return on Capital Employed

Current Company
10.11%
Current Industry
19.5%
EXEL has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

EXEL vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
EXEL$1.83B$312.21M$207.77M+16.47%-22.47%
JAZZ$3.83B$1.22B$414.83M+15.19%-2.54%
CYTK$7.53M-$486.05M-$526.24M-24.89%N/A
CERE$0.00-$416.15M-$432.84MN/AN/A
PCVX$0.00-$392.10M-$402.27MN/AN/A
View Top Biotech Stocks

EXEL earnings dates

Next earnings date
May 30, 2024

Exelixis Earnings & Revenue FAQ

What were EXEL's earnings last quarter?

On Invalid Date, Exelixis (NASDAQ: EXEL) reported Q4 2023 earnings per share (EPS) of $0.27, up 400% year over year. Total Exelixis earnings for the quarter were $85.52 million. In the same quarter last year, Exelixis's earnings per share (EPS) was -$0.09.

If you're new to stock investing, here's how to buy Exelixis stock.

What was EXEL's earnings growth in the past year?

As of Q2 2024, Exelixis's earnings has grown 14.04% year over year. This is 40.13 percentage points lower than the US Biotechnology industry earnings growth rate of 54.16%. Exelixis's earnings in the past year totalled $207.77 million.

What is EXEL's earnings date?

Exelixis's earnings date is Invalid Date. Add EXEL to your watchlist to be reminded of EXEL's next earnings announcement.

What was EXEL's revenue last quarter?

On Invalid Date, Exelixis (NASDAQ: EXEL) reported Q4 2023 revenue of $479.65 million up 13.15% year over year. In the same quarter last year, Exelixis's revenue was $423.92 million.

What was EXEL's revenue growth in the past year?

As of Q2 2024, Exelixis's revenue has grown 13.6% year over year. This is 131.03 percentage points lower than the US Biotechnology industry revenue growth rate of 144.63%. Exelixis's revenue in the past year totalled $1.83 billion.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.